Cadila Healthcare
Cadila Healthcare
Shareholder Return: 3-year, Sales Growth: 3-year CAGR, Return On Equity: 3-year average
At a Glance
-
Shareholder Return122%
-
Sales Growth16%
-
Return on Equity29 %
Why Super 50
With strong growth in domestic and international markets, Cadila continues to be among the top five pharmaceutical companies in India. It has recently acquired two abbreviated new drug applications from Teva (with an estimated market size of $200 million) and the animal health business of Zoetis. It is now focussing on developing biosimilars and grabbing a slice of the $1 billion global biosimilar industry.
